Key leaders in the idiopathic pulmonary fibrosis therapy development industry, representing large pharma and biotech firms, academia and contract research organizations, will gather at the inaugural IPF Summit in Boston, Aug. 21-23. This forum will cover the latest in IPF drug development, from late discovery to early clinical studies.
IPF is a rare, progressive, irreversible, unpredictable disease characterized by progressive scarring (fibrosis) in the lung. The estimated five-year survival rate for people with the condition is 20-40 percent, which makes IPF more rapidly lethal than many cancers. Effective treatments for the condition are a major unmet need.
The IPF Summit has been designed with specific input from experts at leading biopharma and academic institutions. It provides attendees with an opportunity to join thought-leaders to reduce the expansive translational gap that exists in current IPF drug development, and to share insights and network with delegates from key players, including GSK, Bristol-Myers Squibb, Genentech, Patara Pharma, Boehringer Ingelheim, Promedior, and Fibrogen.
The IPF Summit 2017 is solely focused on the preclinical development of novel IPF therapies, and its agenda is dedicated to helping attendees:
• identify and validate novel targets for the development of drugs with different mechanisms of action;
• better model and recapitulate IPF disease;
• explore biomarker and diagnostic strategies that may enable greater clinical application and outcome prediction;
• develop preclinical models that better reflect the disease course and effectively translate IPF’s clinical pathogenesis.
More than 25 expert speakers will participate in the summit, including: Glenn Rosen, head of Discovery Fibrosis Biology at Bristol-Myers Squibb; Craig S. Conoscenti, medical expert in Interstitial Lung Disease Clinical Development at Boehringer Ingelheim Pharmaceuticals; Cory M. Hogaboam, professor of medicine at Cedars-Sinai Medical Center; Joe Arron, senior director of Immunology Research at Genentech; Cynthia Lander, CEO of Moerae Matrix; and Fernando Martinez, executive vice chairman of medicine at Weill Cornell Medical College.
Event organizers say attendees will have the opportunity to join, engage and learn from experts across the IPF field, and will leave the summit “bursting with actionable insights, ideas and solutions to propel your IPF pipeline forward.” A session of speed networking on the first day of the conference will offer attendees the opportunity to meet face-to-face with many of the brightest minds working in the IPF field, and establish meaningful business relationships.